EPZM

Tazverik (Tazemetostat )

Non-Hodgkins Lymphoma

Stage (next event)

Expected Date

Quarterly Sales (Approved)

February 26, 2021

Catalyst Info & Data Links

TITLE: TAZVERIK (tazemetostat) for Non-Hodgkins Lymphoma - Quarterly Sales (Approved)


WHAT IS THE NEXT CATALYST EVENT?

  • Quarterly Sales


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • February 26, 2021


PRIOR DATA

PRESS RELEASES


MECHANISM OF ACTION

  • Inhibition of EZH2 activity may allow for the expression of gene sets that lead to terminal differentiation decisions and germinal center exit1

  • Regardless of oncogenic mutation, follicular lymphoma (FL) tumors have a critical dependence on EZH2 for growth and survival

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon